What Happened?
Cambridge, MA-based eGenesis Appointed Daniel Lynch as Executive Chairman
About the Company
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.
About the Person
Daniel Lynch is Executive Chairman at eGenesis. Previously, Daniel held various senior HR leadership roles in the industry.
Info Source
News
Short Profile